Gallbladder squamous cell carcinoma

Summary

Gallbladder squamous cell carcinoma (MONDO:0006220) is a cancer and 1 clinical trial. Top therapeutic interventions include sorafenib. A subtype of gallbladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gallbladder squamous cell carcinoma
Mondo ID	MONDO:0006220
EFO	EFO:1000267
DOID	DOID:5535
NCIT	C9170
UMLS	C0279658
MedGen	83539
GARD	0024336
Anatomy (UBERON)	UBERON:0002110
Is cancer (heuristic)	yes

Also known as: epidermoid carcinoma of gallbladder · epidermoid carcinoma of the gallbladder · epidermoid gallbladder carcinoma · gall bladder squamous cell carcinoma · gallbladder squamous cell cancer · gallbladder squamous cell carcinoma · squamous cell carcinoma of gallbladder · squamous cell carcinoma of the gallbladder · squamous cell gallbladder carcinoma

Disease family

This is a subtype of gallbladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gallbladder cancer › gallbladder carcinoma › gallbladder squamous cell carcinoma

Related subtypes (4): gall bladder carcinoma in situ, gallbladder adenocarcinoma, gallbladder small cell neuroendocrine carcinoma, undifferentiated gallbladder carcinoma

Subtypes (1): gallbladder adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00238212	PHASE2	COMPLETED	S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SORAFENIB	4	1